ABBV

AbbVie Inc.

276.47 USD

Last updated Oct 10, 08:28 UTC

Yesterday HIGH

$277.6

Yesterday LOW

$270.38

52w HIGH

$277.6

52w LOW

$191

EPS

3.65

PE

75.75

Next Earnings

Oct 30, 2026

Dividends yield

2.76%

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

AbbVie Inc. stock is up 8.42% since 30 days ago. The dividend yield is 2.76% and its next earnings date is Oct 30, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64.29% of the previous 13 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

09 Oct 18:51	20 Nov, 2026	270.00	PUT	52	334
09 Oct 18:51	20 Nov, 2026	260.00	PUT	76	994
09 Oct 18:54	09 Oct, 2026	265.00	CALL	105	460
09 Oct 18:59	20 Nov, 2026	270.00	CALL	48	2366
09 Oct 18:59	15 Jan, 2027	280.00	CALL	60	2491
09 Oct 19:28	09 Oct, 2026	265.00	CALL	32	460
09 Oct 19:37	16 Oct, 2026	265.00	CALL	32	143
09 Oct 19:41	13 Nov, 2026	280.00	CALL	74	14
09 Oct 19:45	30 Oct, 2026	265.00	CALL	19	101
09 Oct 19:47	18 Dec, 2026	260.00	PUT	44	878

Advanced Data Unlock

Benzinga Newsdesk

Wed Sep 30, 2026

AbbVie Says All Three Zumilokibart Dose Regimens Met Primary Endpoint With Significantly Greater EASI-75 Response Vs Placebo At Week 16 In Phase 2 APEX Part B Atopic Dermatitis Study

Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response
Benzinga Insights

Tue Sep 29, 2026

If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.84% on an annualized basis producing an average annual return of 15.37%. Currently, AbbVie has a market capitalization of $465.70 billion.
Benzinga Newsdesk

Tue Sep 29, 2026

CNBC Halftime Report Final Trades: Advanced Micro Devices, AbbVie, SpaceX, Eaton
Avi Kapoor

Tue Sep 29, 2026

UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’

CNBC’s final trades: Weiss picked UnitedHealth, Lebenthal chose AbbVie after FDA approval, and Terranova backed Okta amid raised price targets.
Benzinga Newsdesk

Tue Sep 29, 2026

AbbVie And Valkai Collaborate To Accelerate Pace Of Scientific Innovation's Reach To Patients

AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation
Vandana Singh

Mon Sep 28, 2026

AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says

FDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.
Benzinga Newsdesk

Mon Sep 28, 2026

CNBC Halftime Report Final Trades: Okta, AbbVie, UnitedHealth Group
Benzinga Insights

Mon Sep 28, 2026

8 Of 11 Sectors Fall In Monday Trading As Defensives Lead

Three sectors are higher and eight are lower in Monday’s regular session, with defensive and cyclical sectors split across the top three positions. The leaders are separated rather than clustered.
Benzinga Newsdesk

Mon Sep 28, 2026

AbbVie Receives FDA's Approval For JUVMO To Treat Adults with Parkinson's Disease

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with
Benzinga Newsdesk

Fri Sep 25, 2026

U.S. FDA Approves Juvmo (Tavapadon) For Parkinson’s Disease In Adults On Sept 25, 2026

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

JP Morgan

Thu Oct 8, 22:53

buy

confirm
Cantor Fitzgerald

Thu Oct 8, 12:35

buy

confirm
ScotiaBank

Tue Oct 6, 14:43

buy

confirm
HSBC

Thu Sep 10, 16:10

buy

confirm

Advanced Data Unlock

Susan E Quaggin, Insider

Wed Sep 30, 2026

ABBV Recent Insider Trades and Stock Chart

59 shares awarded
Edward J Rapp, Insider

Wed Sep 30, 2026

ABBV Recent Insider Trades and Stock Chart

129 shares awarded